The biotech initial public offering market is experiencing a strong revival this year after several dry years, Richard Summerfield writes. In the first half of 2013 alone, the value of biotech IPOs surpassed $1.7 billion, more than 2011 and 2012 together. Several factors boosted the popularity of biotech IPOs, including the number of drugs approved last year and the adoption of the Jumpstart Our Business Startups Act.

Related Summaries